News Releases

Summary Toggle Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference

PITTSBURGH, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026, in Boston. Company executives will take part in a fireside chat scheduled at 3:10

February 24, 2026

PDF Version
Summary Toggle Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results

$107.1 million in 4Q VYJUVEK revenue and $730.3 million since U.S. launch FDA granted RMAT to KB707 for the treatment of advanced NSCLC and Fast Track Designation to KB111 for the treatment of HHD Strong balance sheet, ending the quarter with $955.9 million in cash and investments PITTSBURGH, Feb.

February 17, 2026

PDF Version
Summary Toggle Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

PITTSBURGH, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026, prior to the open of U.S. markets.

February 10, 2026

PDF Version
Summary Toggle Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer

PITTSBURGH, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to KB707, the Company’s redosable immunotherapy designed to

February 9, 2026

PDF Version
Summary Toggle Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Preliminary 4Q 2025 VYJUVEK net revenue of $106 million to $107 million Robust clinical pipeline with multibillion dollar opportunities and strong balance sheet for sustained growth PITTSBURGH , Jan. 11, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced

January 11, 2026

PDF Version
Summary Toggle Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis

Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations KB407 transduction confirmed in all six patients with successful bronchoscopies irrespective of modulator-status; percentage of conducting airway cells transduced in each patient ranged

January 8, 2026

PDF Version
Summary Toggle Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis

Investor call to be held January 8 at 4:30 pm ET to discuss data update and next steps PITTSBURGH , Jan. 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that it will host an investor conference call and webcast tomorrow, Thursday, January 8, 2026 ,

January 7, 2026

PDF Version
Summary Toggle Krystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Conference

PITTSBURGH , Jan. 05, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 44 th Annual J.P. Morgan Healthcare Conference on January 12, 2026 , in San Francisco . Krish S.

January 5, 2026

PDF Version
Summary Toggle Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference

PITTSBURGH , Nov. 26, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 8 th Annual Evercore Healthcare Conference on December 3, 2025 , in Miami . Krish S. Krishnan , Chairman and Chief Executive Officer, will

November 26, 2025

PDF Version
Summary Toggle Krystal Biotech Announces Third Quarter 2025 Financial and Operating Results

$97.8 million in 3Q VYJUVEK revenue and $623.2 million since U.S. launch VYJUVEK launched in Germany in 3Q; launched in France and Japan in 4Q Updated U.S. VYJUVEK label expands eligible patient population and provides greater patient flexibility FDA grants platform technology designation CF

November 3, 2025

PDF Version
Summary Toggle Krystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 2025

PITTSBURGH , Oct. 21, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its third quarter 2025 financial results on Monday, November 3, 2025, prior to the open of U.S. markets. The Company’s management will also host a conference call

October 21, 2025

PDF Version
Summary Toggle Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic Keratitis

PITTSBURGH , Oct. 14, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) granted platform technology designation to the genetically modified, non-replicating herpes simplex virus type 1 (HSV-1)

October 14, 2025

PDF Version
Summary Toggle Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label

Revised label allows treatment of DEB patients from birth VYJUVEK can now be applied by patients and caregivers PITTSBURGH , Sept. 15, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) approved a

September 15, 2025

PDF Version
Summary Toggle Krystal Biotech to Present at Cantor Global Healthcare Conference 2025

PITTSBURGH , Sept. 02, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the Cantor Global Healthcare Conference 2025 on September 4, 2025 , in New York . Krish S. Krishnan , Chairman and Chief Executive Officer, will

September 2, 2025

PDF Version
Summary Toggle Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer

PITTSBURGH , Aug. 21, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced an update on development plans for KB707, the Company’s redosable immunotherapy designed to drive sustained, localized expression of

August 21, 2025

PDF Version
Summary Toggle Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results

$96.0 million in 2Q VYJUVEK revenue and $525.4 million since launch in 3Q 2023 VYJUVEK approved in Japan for the treatment of DEB patients from birth Strong balance sheet, ending the quarter with $820.8 million in cash and investments PITTSBURGH , Aug.

August 4, 2025

PDF Version
Summary Toggle Krystal Biotech to Report Second Quarter 2025 Financial Results on August 4, 2025

PITTSBURGH , July 29, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its second quarter 2025 financial results on Monday, August 4, 2025, prior to the open of U.S. markets.

July 29, 2025

PDF Version
Summary Toggle Krystal Biotech Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa

VYJUVEK approved for the treatment of DEB from birth with flexible administration options including home dosing and the option for administration by the patient or their family VYJUVEK is the first and only genetic medicine approved in Japan for the treatment of DEB PITTSBURGH , July 25, 2025

July 25, 2025

PDF Version
Summary Toggle Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté

KB304 designed to deliver collagen and elastin to restore skin naturally Conference call to discuss results scheduled for Thursday, July 24, 2025 at 4:30pm ET PITTSBURGH , July 24, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc.

July 24, 2025

PDF Version
Summary Toggle Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis

Eye drop administration of KB801 designed to enable sustained expression of NGF in the front of the eye Investor call and webcast to be held July 9 at 8:30 am ET to discuss program and trial design PITTSBURGH , July 09, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc.

July 9, 2025

PDF Version
Summary Toggle Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa

Intra-patient, double-blind, multicenter, placebo-controlled study with crossover design Repeat administration under compassionate use was previously shown to be well tolerated and associated with full corneal healing by 3 months as well as significant visual acuity improvement from hand motion to

June 24, 2025

PDF Version
Summary Toggle Krystal Biotech to Present at Goldman Sachs 46th Annual Global Healthcare Conference

PITTSBURGH , June 03, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the Goldman Sachs 46 th Annual Global Healthcare Conference on June 10, 2025 , in Miami . Krish S.

June 3, 2025

PDF Version
Summary Toggle Krystal Biotech to Present at BofA Securities 2025 Health Care Conference

PITTSBURGH , May 07, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the BofA Securities 2025 Health Care Conference on May 14, 2025 , in Las Vegas . Krish S. Krishnan , Chairman and Chief Executive Officer, will

May 7, 2025

PDF Version
Summary Toggle Krystal Biotech Announces First Quarter 2025 Financial and Operating Results

VYJUVEK approved in Europe for the treatment of DEB patients from birth $88.2 million in 1Q VYJUVEK revenue and $429.4 million since launch in Q3 2023 Second ophthalmic program in clinic - KB801 for the treatment of neurotrophic keratitis Upcoming clinical readouts in 2025 - CF, AATD, ocular

May 6, 2025

PDF Version
Summary Toggle Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

VYJUVEK approved for the treatment of DEB from birth in Europe Approval allows for dosing at home or in a healthcare setting, as well as patient or caregiver administration if deemed appropriate by a healthcare professional PITTSBURGH , April 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc.

April 28, 2025

PDF Version
Summary Toggle Krystal Biotech to Present at Upcoming Scientific Conferences

PITTSBURGH , April 24, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the Company will be presenting on multiple programs in the lung, eye, and skin at upcoming scientific conferences being held in May and June.

April 24, 2025

PDF Version
Summary Toggle Krystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025

PITTSBURGH , April 17, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 6, 2025, prior to the open of U.S. markets.

April 17, 2025

PDF Version
Summary Toggle Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer

PITTSBURGH , April 07, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) leveraging Krystal’s clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced

April 7, 2025

PDF Version
Summary Toggle Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

EC approval decision anticipated in second quarter of 2025 PITTSBURGH , Feb. 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA’s) announcement that its Committee for

February 28, 2025

PDF Version
Summary Toggle Krystal Biotech to Present at TD Cowen 45th Annual Health Care Conference

PITTSBURGH , Feb. 26, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the TD Cowen 45th Annual Health Care Conference on March 4, 2025 , in Boston . Krish S.

February 26, 2025

PDF Version
Summary Toggle Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results

Fourth quarter revenues increased 116% to $91.1 million versus fourth quarter of 2023 Full year revenues increased 473% to $290.5 million versus 2023 CFF TDN granted full sanctioning of KB407 Phase 1 protocol Strong balance sheet, ending the quarter with $749.6 million in cash and investments

February 19, 2025

PDF Version
Summary Toggle Krystal Biotech to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

PITTSBURGH , Feb. 06, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its fourth quarter and full year 2024 financial results on Wednesday, February 19, 2025 , prior to the open of U.S.

February 6, 2025

PDF Version
Summary Toggle Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer

PITTSBURGH , Jan. 14, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) leveraging Krystal’s clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced

January 14, 2025

PDF Version
Summary Toggle Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer

Preliminary clinical data in post-anti-PD-1 NSCLC patients demonstrated a 27% ORR and 73% DCR in monotherapy trial Monotherapy activity with inhaled KB707 provides further evidence of successful repeat administration of HSV-1 based inhaled lung gene delivery and builds on recent clinical data

December 18, 2024

PDF Version
Summary Toggle Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of AATD Patients and Increase in Lung AAT to Therapeutic Levels

Clear evidence of SERPINA1 gene delivery and AAT expression following KB408 administration in AATD patients Both KB408 for AATD patients and KB407 for patients with cystic fibrosis were safe and well tolerated at all dosing regimens evaluated to date Conditional sanctioning of the KB407 Phase 1 CF

December 12, 2024

PDF Version
Summary Toggle Krystal Biotech Provides Update on EMA’s Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa

CHMP opinion now expected in 1Q 2025 No Major Objections outstanding; continue to expect Germany launch in 2Q 2025 PITTSBURGH , Dec. 09, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the European

December 9, 2024

PDF Version
Summary Toggle Krystal Biotech to Present at Upcoming Investor Conferences

PITTSBURGH , Nov. 27, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that Krish S. Krishnan , Chairman and Chief Executive Officer, will take part in fireside chats and host investor meetings at two upcoming

November 27, 2024

PDF Version
Summary Toggle Krystal Biotech to Present at Stifel 2024 Healthcare Conference

PITTSBURGH , Nov. 12, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Stifel 2024 Healthcare Conference on November 18, 2024 , in New York . Krish S.

November 12, 2024

PDF Version
Summary Toggle Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference

PITTSBURGH , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Guggenheim Securities Healthcare Innovation Conference on November 12, 2024 , in Boston . Krish S.

November 6, 2024

PDF Version
Summary Toggle Krystal Biotech Announces Third Quarter 2024 Financial Results and Provides Business Updates

Net product revenue of $83.8 million in 3Q and $250.1 million since launch in August 2023 JNDA for B-VEC filed and on track for commercial launches in Japan and Europe in 2025 French health authority approved pre-marketing early reimbursed access for B-VEC in France under the Accès Précoce (AP1)

November 4, 2024

PDF Version
Summary Toggle Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024

PITTSBURGH , Oct. 28, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its third quarter 2024 financial results on Monday, November 4, 2024, prior to the open of U.S. markets.

October 28, 2024

PDF Version
Summary Toggle Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference

PITTSBURGH , Sept. 13, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the 2024 Cantor Global Healthcare Conference on September 18, 2024 , in New York . Krish S.

September 13, 2024

PDF Version
Summary Toggle Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

PITTSBURGH , Sept. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024 , in New York .

September 6, 2024

PDF Version
Summary Toggle Jeune Aesthetics Announces Phase 1 Positive Interim Safety and Efficacy Results for KB301 in the Treatment of Lateral Canthal Lines and Dynamic Wrinkles of the Décolleté

Décolleté indication selected for Phase 2 study expected to start next year Conference call to discuss results scheduled for Wednesday, August 28, 2024 at 4:30 p.m. ET PITTSBURGH , Aug. 28, 2024 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc.

August 28, 2024

PDF Version
Summary Toggle Krystal Biotech Announces Second Quarter 2024 Financial Results and Provides Business Updates

Net product revenue of $70.3 million in 2Q and $166.2 million since launch in August 2023 On track to deliver three clinical readouts in 2H 2024 Jeune Aesthetics’ KB301 Phase 1 PEARL-1 study (Cohorts 3 and 4) in 3Q 2024; KB408 Phase 1 SERPENTINE-1 study for the treatment of AATD in 4Q 2024; and

August 5, 2024

PDF Version
Summary Toggle Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024

PITTSBURGH , July 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its second quarter 2024 financial results on Monday, August 5, 2024, prior to the open of U.S. markets.

July 26, 2024

PDF Version
Summary Toggle Krystal Biotech to Present at Goldman Sachs 45th Annual Global Healthcare Conference

PITTSBURGH , June 05, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Goldman Sachs 45 th Annual Global Healthcare Conference on June 11, 2024 , in Miami . Krish S.

June 5, 2024

PDF Version
Summary Toggle Krystal Biotech to Present at the American Thoracic Society 2024 International Conference

PITTSBURGH , May 15, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new preclinical data on respiratory genetic medicine candidates KB407 and KB408 at the American Thoracic

May 15, 2024

PDF Version
Summary Toggle Krystal Biotech to Present at BofA Securities 2024 Health Care Conference

PITTSBURGH , May 08, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the BofA Securities 2024 Health Care Conference on May 14, 2024 , in Las Vegas . Krish S.

May 8, 2024

PDF Version
Summary Toggle Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates

Net product revenue of $45.3 million in 1Q and $95.9 million since August First patient dosed in inhaled KB707 study for locally advanced or metastatic tumors of the lung Received Fast Track Designations for both inhaled and intratumoral KB707 Strong balance sheet with $622.3 million in cash and

May 6, 2024

PDF Version

Investors

News Releases